Itrabene

Itraconazole, the active ingredient in Itrabene, is a azole antifungal presented as a oral formulation for oral use. It treats systemic and localized fungal infections in adults and children as prescribed by a healthcare professional.

GNH USA supplies Itrabene as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itraconazole is used to treat a range of deep‑tissue and superficial fungal infections by inhibiting ergosterol synthesis. - Blastomycosis: eradicates the causative Blastomyces dermatitidis and resolves pulmonary and disseminated disease. - Histoplasmosis: clears Histoplasma capsulatum infection, improving respiratory and systemic symptoms. - Aspergillosis: controls invasive Aspergillus species, reducing tissue invasion and mortality. - Systemic Candidiasis: eliminates Candida spp. from bloodstream and internal organs. - Dermatophytosis: treats skin‑surface dermatophyte infections, promoting lesion healing. - Sporotrichosis: combats Sporothrix schenckii, preventing spread along lymphatic channels.

Adverse reactions to itraconazole vary from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional emesis. - Abdominal pain: cramping or discomfort. - Headache: transient dull pain. - Rash: skin redness or itching. - Taste disturbance: altered taste perception.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - QT prolongation: cardiac rhythm disturbances. - Hepatic failure: rare but life‑threatening liver dysfunction. - Anaphylaxis: acute allergic response requiring emergency care.

When prescribing itraconazole, clinicians should consider several safety measures. - Liver function monitoring: assess baseline and periodic hepatic enzymes. - Drug interaction vigilance: review concomitant medications for CYP3A4 substrates. - Cardiac assessment: avoid in patients with known QT prolongation. - Hypersensitivity caution: discontinue if allergic reactions occur. - Renal impairment use: adjust dosing in severe kidney disease. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Itraconazole has a broad interaction profile that requires careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may cause toxic itraconazole levels. - Certain statins (simvastatin, lovastatin): increased risk of rhabdomyolysis. - Anti‑arrhythmic agents (quinidine, amiodarone): heightened cardiac toxicity. - HIV protease inhibitors (indinavir): unpredictable plasma concentrations. - Macrolide antibiotics (clarithromycin): elevated itraconazole exposure.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (midazolam, cyclosporine): may require dose adjustment. - Calcium channel blockers (verapamil, diltiazem): monitor for enhanced effects. - Oral contraceptives: reduced efficacy, advise alternative contraception. - Warfarin: possible increased anticoagulant effect, check INR. - Antifungal combination therapy: assess for additive toxicity.